Predictive value of IL-10 and GFPA for postoperative prognosis in patients with brain glioma.

Objective: To investigate the prognostic value of interleukin (IL)-10 and glial fibrillary acidic protein (GFPA) in patients with brain glioma following surgery.

Methods: The clinical data of 75 patients with brain glioma (Observation group) who were treated at the Central Hospital Affiliated with Shandong First Medical University were retrospectively analyzed. Additionally, 40 healthy volunteers who underwent physical examination during the same period were selected as the control group.

Tumor-derived Immunoglobulin-like transcript 4 facilitates angiogenesis of colorectal cancer.

Current anti-angiogenic therapies have changed the paradigm of treating colorectal cancer (CRC) patients with advanced diseases. However, the clinical response rate is still low at less than 10% due largely to complex angiogenic factors released by tumor cells. Exploring novel mechanisms of tumor angiogenesis and identifying alternative targets for combination therapies are therefore essential to effective inhibition of tumor vascularization and CRC development.

Roles of Krüppel-like factor 6 splice variant 1 in the development, diagnosis, and possible treatment strategies for non-small cell lung cancer.

Krüppel-like factor 6 (KLF6) is a nuclear transcriptional regulator found in mammalian tissue that has been identified as a tumor suppressor gene in several malignancies. As a result of loss of heterozygosity, DNA methylation, and alternative splicing, it is frequently inactivated in various malignancies. Krüppel-like factor 6 splice variant 1 (KLF6-SV1), Krüppel-like factor 6 splice variant 2, and Krüppel-like factor 6 splice variant 3 alternatively spliced isoforms that emerge from a single nucleotide polymorphism in the KLF6 gene.

The combined detection of autoantibody characteristics in systemic lupus erythematosus.

Objective: To investigate the combined detection of the autoantibody characteristics in systemic lupus erythematosus (SLE).

Methods: 105 SLE patients admitted to our hospital from May 2019 to September 2020 were placed in the SLE examination group (the SE group), 110 patients with rheumatic diseases admitted to our hospital during the same period were placed in the disease control group (the DC group), and 100 healthy people who came to our hospital for physical examinations during the same time period were placed in the healthy control group (the HC group). The SLE patients' clinical data were recorded.